Clinical Observation of Phacoemulsification Combined with Intravitreal Injection of Conbercept in Cataract Patients with Diabetic Macular Edema

Wang, Jing; Liu, Yuqi; Hu, Yiping; Lu, Lu; Tang, Kaili; Zhang, Jinsong

doi:10.1155/2021/8849730

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intravitreal administration of anti-VEGF drugs can rapidly improve DME symptoms and has attracted significant clinical attention. Conbercept is a humanized anti-VEGF drug manufactured domestically and with a strong presence in the domestic market, available for treating ocular vascular diseases with remarkable results[ 5 ]. This study aimed to evaluate the combined effects of conbercept intravitreal administration and laser retinal photocoagulation for DME, compare the effects of combined treatment and laser photocoagulation alone, and propose a new clinical treatment system for DME in DR.…”

Section: Introductionmentioning

confidence: 99%

Conbercept combined with laser photocoagulation in the treatment of diabetic macular edema and its influence on intraocular cytokines

Zhan¹,

Zhou²,

Zhang³

et al. 2023

World J Diabetes

View full text Add to dashboard Cite

The incidence of type 2 diabetes mellitus is growing in epidemic proportions and has become one of the most critical public health concerns. Cardiovascular complications associated with diabetes are the leading cause of morbidity and mortality. The cardiovascular diseases that accompany diabetes include angina, myocardial infarction, stroke, peripheral artery disease, and congestive heart failure. Among the various risk factors generated secondary to hyperglycemic situations, advanced glycation end products (AGEs) are one of the important targets for future diagnosis and prevention of diabetes. In the last decade, AGEs have drawn a lot of attention due to their involvement in diabetic patho-physiology. AGEs can be derived exogenously and endogenously through various pathways. These are a nonhomogeneous, chemically diverse group of compounds formed nonenzymatically by condensation between carbonyl groups of reducing sugars and free amino groups of protein, lipids, and nucleic acid. AGEs mediate their pathological effects at the cellular and extracellular levels by multiple pathways. At the cellular level, they activate signaling cascades via the receptor for AGEs and initiate a complex series of intracellular signaling resulting in reactive oxygen species generation, inflammation, cellular proliferation, and fibrosis that may possibly exacerbate the damaging effects on cardiac functions in diabetics. AGEs also cause covalent modifications and cross-linking of serum and extracellular matrix proteins; altering their structure, stability, and functions. Early diagnosis of diabetes may prevent its progression to complications and decrease its associated comorbidities. In the present review, we recapitulate the role of AGEs as a crucial mediator of hyperglycemia-mediated detrimental effects in diabetes-associated complications. Furthermore, this review presents an overview of future perspectives for new therapeutic interventions to ameliorate cardiovascular complications in diabetes.

show abstract

Section: Introductionmentioning

confidence: 99%